No approved hantavirus vaccine exists for widespread use, and all current candidates remain in early development, driving the market's 97.5% implied probability of no approval by the end of 2026. Preclinical mRNA candidates, such as single-dose formulations tested in hamster models against Andes virus, have shown strong immunogenicity and protection, while DNA and MVA-based candidates have completed only small Phase 1 trials assessing safety and neutralizing antibodies. The rarity of cases complicates large-scale efficacy trials, and regional strain diversity adds further hurdles without accelerated regulatory pathways or major new funding. A late-2026 emergency use authorization could theoretically shift outcomes following intensified outbreaks, though current timelines and data make this improbable.